TCRR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCRR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TCR2 Therapeutics's annualized net income for the quarter that ended in Mar. 2023 was $-161.60 Mil. TCR2 Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2023 was $121.09 Mil. Therefore, TCR2 Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 was -133.45%.
The historical rank and industry rank for TCR2 Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
During the past 7 years, TCR2 Therapeutics's highest Return-on-Tangible-Equity was -33.82%. The lowest was -127.35%. And the median was -55.22%.
The historical data trend for TCR2 Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCR2 Therapeutics Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Return-on-Tangible-Equity | Get a 7-Day Free Trial | - | -127.35 | -33.82 | -38.53 | -71.90 |
TCR2 Therapeutics Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -43.40 | -52.50 | -57.61 | -142.61 | -133.45 |
For the Biotechnology subindustry, TCR2 Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TCR2 Therapeutics's Return-on-Tangible-Equity falls into.
TCR2 Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -151.822 | / | ( (281.477 | + | 140.859 ) | / 2 ) | |
= | -151.822 | / | 211.168 | ||||
= | -71.90 % |
TCR2 Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Mar. 2023 ) | (Q: Dec. 2022 ) | (Q: Mar. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Mar. 2023 ) | (Q: Dec. 2022 ) | (Q: Mar. 2023 ) | |||||
= | -161.596 | / | ( (140.859 | + | 101.33) | / 2 ) | |
= | -161.596 | / | 121.0945 | ||||
= | -133.45 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
TCR2 Therapeutics (NAS:TCRR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of TCR2 Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Ansbert Gadicke | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Mpm Asset Management Llc | 10 percent owner | 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Shawn Tomasello | director | C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Priti Hegde | director | TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142 |
Rosemary Harrison | officer: Chief Business & Strategy | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Garry E Menzel | director, officer: President & CEO | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Peter Olagunju | officer: Chief Technical Officer | TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142 |
Alfonso Quintas Cardama | officer: Chief Medical Officer | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Angela Justice | officer: Chief People Officer | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Eric Sullivan | officer: Chief Financial Officer | GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109 |
Mayur Ian Somaiya | officer: Chief Financial Officer | TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Axel Hoos | director | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 09-01-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By Value_Insider Value_Insider • 11-01-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 05-02-2022
By Stock market mentor Stock market mentor • 02-08-2023
By GuruFocus Research GuruFocus Editor • 12-08-2022
By sperokesalga sperokesalga • 05-08-2023
By GuruFocus Research GuruFocus Editor • 12-06-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.